The AngelMed Guardian device is implanted similar to a pacemaker. Credit: PRNewsfoto/Hydrix Limited.

Technology company Hydrix has partnered with medical device developer Angel Medical Systems (AngelMed) for exclusive rights to distribute a heart attack alerting device in Australia.

Furthermore, the deal allows Hydrix to provide the AngelMed Guardian System in multiple other Asian markets, including Japan and Singapore.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Guardian is a cardiac monitoring device to notify patients in case of an imminent acute coronary syndrome (ACS) episode such as heart attacks and unstable angina, designed for patients with a history of ACS and who are at high risk for recurrent episodes.

The device offers continuous monitoring of a patient’s heart signal and leverages artificial intelligence (AI) to identify an impending heart attack.

Upon identification of suspicious heart activity, the AngelMed Guardian System instantly alerts the patient via vibration within the chest. Also, a separate wireless device notifies patients with sound and flashing LEDs.

The implant detects ACS symptoms accurately than the patient alone. Guardian is meant to minimise the uncertainty associated with self-diagnosis, added the company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Around 900 patients were implanted with the device in clinical trials performed in the US.

Data showed lower morbidity rates, better patient quality of life, decrease in heart damage and length of hospital stay, resulting in reduced healthcare costs for patients.

Hydrix CEO Peter Lewis said: “The Guardian is part of Hydrix’s commitment to developing products and technologies which help improve the quality of life for patients around the world.

“We look forward to a long relationship with AngelMed as we help make the Guardian System become the new standard of cardiac patient care in the Asia Pacific.”

The Guardian System is scheduled to launch in Australia in 2021, subject to regulatory approval.